Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Intercell raises $34 million

Vaccine company Intercell (Vienna, Austria) raised $34 million

Read the full 80 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE